What We're Reading: Page
Industry reads hand-picked by our editors
Mar 22, 2023
Mar 21, 2023
-
The Boston Globe
Boston scientists say they’re a step closer to growing human eggs in the lab
-
Grid News
The big psychedelic therapy debate: To trip or not to trip?
-
Endpoints News
‘No finding of research misconduct’: MIT ends 3.5-year review of biotech founder, professor Sasisekharan
-
Science
Polio cases in Africa linked to new oral vaccine
Mar 20, 2023
-
Financial Times
Big Pharma lobbies for slice of US chip industry tax breaks
-
NPR
California enters a contract to make its own affordable insulin
-
Reuters
Novo Nordisk’s diabetes drug Ozempic back in supply in US after months of shortage
-
BioSpace
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
Mar 17, 2023
Mar 16, 2023
-
The Wall Street Journal
Shortage of Last-Ditch Drug for Advanced Prostate Cancer Worries Doctors
-
Reuters
Alzheimer’s Association lobbies for Medicare coverage of Leqembi and other drugs
-
Fierce Biotech
The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq?
-
WBUR
This Mass. doctor questioned a popular pregnancy drug. Now, he’s been proven right
Mar 15, 2023
-
GeekWire
How Pfizer’s $43 billion acquisition of Seagen could impact the biotech industry in Seattle
-
Evaluate Vantage
Europe rues SVB loss as a cornerstone life science supporter
-
Reuters
How GSK plans to replenish its depleted medicine cabinet
-
Fierce Pharma
Chasing Pfizer, GSK’s 5-in-1 meningococcal vaccine delivers phase 3 trial win
Mar 14, 2023
-
C&EN
Why lecanemab’s success spells the revival of small-molecule Alzheimer’s disease treatments
-
Legal Dive
SVB had no risk chief through much of 2022, proxy statement shows
-
Reuters
U.S. FDA places Mersana’s cancer drug trial on hold following death
-
Bloomberg
Novartis Is Said to Start Sale of Some Ophthalmology Assets
Previous
